Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.
about
HPV Associated Head and Neck CancerThe promise of immunotherapy in head and neck squamous cell carcinomaTargeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinomaModulation of therapeutic sensitivity by human papillomavirusManagement of Oropharyngeal Cancer in the HPV Era.Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx.Increased malignancy of oral squamous cell carcinomas (oscc) is associated with macrophage polarization in regional lymph nodes - an immunohistochemical studyIntegrated omic analysis of oropharyngeal carcinomas reveals human papillomavirus (HPV)-dependent regulation of the activator protein 1 (AP-1) pathway.In Vitro-Stimulated IL-6 Monocyte Secretion and In Vivo Peripheral Blood T Lymphocyte Activation Uniquely Predicted 15-Year Survival in Patients with Head and Neck Squamous Cell Carcinoma.The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategiesA subset of myofibroblastic cancer-associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers.Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients.Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma.Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancerA beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequencyOropharyngeal squamous cell carcinomas differentially express granzyme inhibitors.Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines.PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100The immune response in HPV(+) oropharyngeal cancer.Biomarkers in anal cancer: from biological understanding to stratified treatment.Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy.Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors.Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options.Evaluating the effect of immune cells on the outcome of patients with mesothelioma.Characterisation of the cancer-associated glucocorticoid system: key role of 11β-hydroxysteroid dehydrogenase type 2.Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.Applications of molecular diagnostics for personalized treatment of head and neck cancer: state of the art.Antigen processing and immune regulation in the response to tumours.The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside.Risk Groups for Survival in HPV-Positive and HPV-Negative OPSCC.Novel Approaches for Vaccination Against HPV-Induced Cancers.TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?Crowdsourcing for translational research: analysis of biomarker expression using cancer microarrays.Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neckAn adaptive immune response driven by mature, antigen-experienced T and B cells within the microenvironment of oral squamous cell carcinoma.
P2860
Q26741386-256148AF-6E76-4759-BDB2-2C5A598E09FDQ26744433-6076A9DC-6F5C-4521-94AB-F5A9A20FCCFAQ26765429-763B28C5-C8D5-47F1-9393-AA0A5954E41DQ28085367-DF03E4F2-3679-4F45-9F73-3A1065DC4FADQ28087031-3188529F-BF3E-4328-BE21-C974640C17F4Q30248326-24D73AD2-9156-40E4-9B78-03A50232308BQ33816576-95FE2B7D-9BCF-4A87-9093-3EF6C5C9768EQ34468743-91B61D74-F791-4B7E-9D92-D136AC2DCEBAQ34635004-C208C8B3-4400-41C6-9CD7-FD1C51D26CB9Q35664923-44A36561-98A1-4404-BCDC-F06FB1C3BC5BQ35838231-1A48433E-C3D9-461C-9BA8-9B75244E322EQ35881485-2A105E5E-C5FA-4A5A-8C78-9669B92897C1Q35927872-8FF9C1BA-7AD8-449D-B033-BD97AEA28B35Q36081369-B998DD3E-2D0E-426C-860E-242EA3033974Q36750751-3ADCED6B-8A14-48B9-8C6F-1F007490ED5FQ36783066-875E33BF-D8DA-4DD4-B4B3-D4660B31789CQ36823719-DA89C7C4-B2FB-423D-8287-7CB4F07076B5Q36919512-EADDCFCD-6944-4BBA-BBF2-166EF6E4FD45Q37085912-E8ECADA5-320C-492E-97C1-8912DF95E4DCQ37489634-C56CBB99-0D2F-4991-B13A-816296910EE3Q37562953-43319F76-3534-43DF-93E2-D74B5BD3744CQ37592879-3B6F53A2-BBBB-48A1-BF4C-BD2C820B6F8EQ37619757-576D1D6C-714A-4B5B-947E-BB4939A2A230Q37636535-5C552605-6E2E-49F0-B3AA-0D907F37F1F7Q38217028-E8DC89A8-12F3-4675-BC20-C3CB96873094Q38252802-F0E3A6B9-AE13-4296-97FD-DF18CE59ECA9Q38619743-E8B076DC-63BF-4280-9C38-24B5D80C7639Q38630295-F55CF03F-1810-4627-A2E8-FD8A31B3101BQ38636573-94F513F9-CDDB-43BE-9A01-E27C2427323DQ38653658-92EE2167-D665-4FEE-A23E-6D676BC096BAQ38818628-DEF3474B-C029-4E7A-AACA-5DAB4E620F5EQ38833182-9568441B-30C9-460D-96D1-0C0533B434D2Q38858806-198FE27A-7DF9-4B19-B303-0F475E7C1794Q38971577-89028B6D-89FA-4FD3-9E2D-936274E45414Q39033362-0405D581-56C6-4269-9E59-693D8C6531EDQ39055075-41A99CA4-DD07-48BF-B56F-A2D5503CEF55Q39105241-BE2F1329-ACE4-411A-A023-4073214162B0Q39187442-FA20EFF3-5A2A-4A06-8BD4-1823EC12D5DAQ39999283-0D60A83B-ADA9-49D7-932E-9EF3002BBE40Q40056727-7B99C991-891C-43D6-9D7F-FD24C27488CA
P2860
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.
@en
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.
@nl
type
label
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.
@en
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.
@nl
prefLabel
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.
@en
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.
@nl
P2093
P2860
P356
P1476
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer
@en
P2093
C J Randall
G J Thomas
P2860
P2888
P304
P356
10.1038/BJC.2013.639
P407
P577
2013-10-29T00:00:00Z